Developer docs
API playgroundTry for free, no card

Search company profiles

Aravax

Full company profile

uuid0000nl3

Namestring
Aravax
Legal namestring
Aravax Pty Ltd
Websiteurl
aravax.com.au
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Aravax is a clinical-stage biotechnology company founded in 2015 as a spinout from Alfred Health and Monash University in Melbourne, Australia, focused on developing next-generation peptide-based immunotherapies for food allergy. Its lead product candidate, PVX108, is composed of seven proprietary peptides representing immuno-dominant T-cell epitopes from major peanut allergens; the peptides are designed to retrain allergen-specific CD4+ T cells upstream of IgE-mediated processes without containing whole peanut proteins or triggering treatment-induced anaphylaxis. The candidate is administered as a monthly intradermal injection (0.1 mL) with no dose escalation required, differentiating from existing oral and epicutaneous approaches on safety, convenience, and disease-modifying mechanism. Phase 1 trials demonstrated a favorable safety profile even in patients with asthma and prior anaphylaxis, and a 95-patient Phase 2 study (AVX-201) is fully enrolled across 14 sites in the United States and Australia, with headline results expected in H1 2026.

The company is pre-revenue and funded primarily through venture capital, having closed a US$42.2M Series B in January 2024 led by Brandon Capital and Tenmile and joined by Novartis Venture Fund, Breakthrough Victoria, Uniseed, UniSuper, and Agati Capital. Its future revenue model contemplates one-time product licensing and pharmaceutical sales of PVX108 and pipeline food-allergy immunotherapies following regulatory approval, distributed eventually through allergists, immunologists, specialty pharmacies, and healthcare providers. Commercial readiness is being built through a UK subsidiary at the Oxford Science Park (established November 2024) for peptide manufacturing process development, alongside senior commercial, regulatory, and CMC hires. Aravax's go-to-market motion today centers on international clinical trial execution (Phase 2 under US IND and Australian regulatory frameworks), scientific engagement at conferences such as EAACI and AAAAI, and academic collaborations with Stanford, Benaroya Research Institute, and Murdoch Children's Research Institute.

Short descriptiontext

Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy designed to safely retrain the immune system to tolerate peanut allergens. The Melbourne-headquartered firm is running an international Phase 2 trial in children and adolescents ahead of a future commercial launch targeting allergists and food-allergy patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide immunotherapy, peanut allergy treatment, biopharmaceutical research, food allergy therapies, clinical stage biotechnology
Industry1 code
PRIMARYHLAKAAAF
Allergen Immunotherapy (SCIT/SLIT) Services
Product category
Allergy Immunotherapy Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue (Future)
TypeOne Time License
Description

Pre-commercial biotech company. Future revenue expected from sale of PVX108 and pipeline immunotherapy products for food allergies upon regulatory approval. The company is preparing for Phase 3 trials and eventual market launch.

aravax.com.au
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy composed of seven proprietary peptides targeting T cells for the treatment of peanut allergy. The therapy is delivered via monthly intradermal injection and is designed to retrain the immune system to tolerate peanut proteins without triggering treatment-induced acute allergic reactions. The company is currently running international Phase 2 clinical trials in the US and Australia and is preparing for Phase 3 development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 trials demonstrated PVX108 was safe and well tolerated in participants with peanut allergy, including participants with asthma and prior anaphylaxis to peanut
+2 more records
Product overview1 text field

Aravax is a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy. Its lead product candidate, PVX108, is a peptide-based immunotherapy in Phase 2 clinical trials for peanut allergy treatment. The company's proprietary platform uses engineered peptides to precisely target T cells and retrain the immune system to tolerate specific foods without triggering treatment-induced allergic reactions.

Product and service1 record
1PVX108
CategoryAllergy Immunotherapy Pharmaceutical (Investigational)
Description

PVX108 is Aravax's lead peanut allergy immunotherapy candidate, composed of seven proprietary peptides representing immuno-dominant T cell epitopes from major peanut allergens. It is designed to retrain the immune system to tolerate peanut proteins by precisely targeting allergen-specific T cells, while avoiding the acute allergic reactions triggered by whole-allergen therapies. It is administered monthly via intradermal injection (0.1 mL) with no dose escalation required, and is being developed for children and adolescents (aged 4-17) with peanut allergy.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration established January 2017. Erik Wambre's research group in Seattle collaborates on immunological response research. BRI received $5M NIH grant to support investigations into immune mechanisms of PVX108.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration established November 2017 with Professor Kari Nadeau's group at Sean N. Parker Centre for Allergy and Asthma Research. Collaborates on exploring immunological responses to PVX108 using clinical samples from trials.

3Monash University
Strategic tierCoreTypeTechnology or Integration
Description

Technology and IP originated from Monash University and Alfred Health in 2015. Co-founder Sara Prickett held senior research posts here.

aravax.com.au
Strategic tierCoreTypeTechnology or Integration
Description

Technology and IP originated from Alfred Health and Monash University in 2015. Research led by Professor Robyn O'Hehir's team.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase 2 (AVX-201) led by Associate Professor Kirsten Perrett. Also leads National Allergy Centre of Excellence.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Circassia Pharmaceuticals
TypeBroad incumbent
Description

Circassia is a UK-based allergy and respiratory specialty pharmaceutical company with a portfolio of allergy diagnostics and treatments. Several Aravax executives (Pascal Hickey, Paul Laidler, Adrian Parry, Louise Peacock) previously held senior roles at Circassia, indicating deep talent and strategic overlap in allergy therapeutics.

TypeEmerging player
Description

Intrommune is developing a peanut allergy immunotherapy delivered via a toothpaste-based oral mucosal platform. It is an emerging player in the peanut allergy space using a differentiated delivery mechanism but targeting the same patient population.

TypeDirect peer
Description

Aimmune developed and commercialized Palforzia, the first FDA-approved oral immunotherapy for peanut allergy. It is the most directly comparable company to Aravax in peanut allergy immunotherapy, with overlapping target indication and clinical-stage development path. Andrew Oxtoby (now on Aravax's board) was previously CCO at Aimmune.

4Alladapt Immunotherapeutics
TypeDirect peer
Description

Alladapt is developing a multi-food allergen immunotherapy for peanut plus other foods, with a similar mechanism approach (allergen-specific immune modulation). Louise Peacock, Aravax's Chief Regulatory and Quality Officer, previously held the same role at Alladapt, indicating direct competitive and talent overlap.

TypeDirect peer
Description

DBV develops Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. It is a direct competitor in the food allergy immunotherapy space using an alternative delivery modality (patch vs Aravax's intradermal peptide), targeting the same patient population and allergist channel.

TypeBroad incumbent
Description

Stallergenes Greer is a global leader in allergen immunotherapy, offering SCIT and SLIT products for respiratory and venom allergies. It is a broader incumbent in the allergy immunotherapy category relevant to Aravax's target market of allergists and represents the established commercial infrastructure Aravax will eventually need to compete with or partner through.

TypeEmerging player
Description

Vedanta is developing microbiome-based immunotherapies including for food allergy. While mechanism differs (commensal bacteria vs peptide), it targets the same underlying indication category and represents an emerging competitive approach in food allergy treatment that Aravax will need to position against.

TypeEmerging player
Description

Prota Therapeutics (formerly Prota Kids) is developing peanut oral immunotherapy with a probiotic-based approach, in clinical-stage development for peanut allergy. It is a direct emerging competitor in peanut allergy immunotherapy with overlapping indication and allergy-specialist channel.

TypeEmerging player
Description

COUR Pharmaceuticals develops nanoparticle-based antigen-specific immune tolerance therapies for food allergies including peanut. It represents an emerging approach (antigen-loaded nanoparticles) intersecting with Aravax's peptide immunotherapy space in the same indication and prescriber audience.

TypeBroad incumbent
Description

ALK-Abello is the dominant global player in allergy immunotherapy (SCIT/SLIT tablets) and the most established commercial competitor in the broader allergy space. Carsten Hellmann, former CEO of ALK-Abello, is on Aravax's board, signaling strategic overlap and a potential partnership/acquisition path.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aravax

Allergy Immunotherapy Pharmaceuticalsaravax.com.au

Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy designed to safely retrain the immune system to tolerate peanut allergens. The Melbourne-headquartered firm is running an international Phase 2 trial in children and adolescents ahead of a future commercial launch targeting allergists and food-allergy patients.

What Aravax does

Aravax is a clinical-stage biotechnology company founded in 2015 as a spinout from Alfred Health and Monash University in Melbourne, Australia, focused on developing next-generation peptide-based immunotherapies for food allergy. Its lead product candidate, PVX108, is composed of seven proprietary peptides representing immuno-dominant T-cell epitopes from major peanut allergens; the peptides are designed to retrain allergen-specific CD4+ T cells upstream of IgE-mediated processes without containing whole peanut proteins or triggering treatment-induced anaphylaxis. The candidate is administered as a monthly intradermal injection (0.1 mL) with no dose escalation required, differentiating from existing oral and epicutaneous approaches on safety, convenience, and disease-modifying mechanism. Phase 1 trials demonstrated a favorable safety profile even in patients with asthma and prior anaphylaxis, and a 95-patient Phase 2 study (AVX-201) is fully enrolled across 14 sites in the United States and Australia, with headline results expected in H1 2026.

The company is pre-revenue and funded primarily through venture capital, having closed a US$42.2M Series B in January 2024 led by Brandon Capital and Tenmile and joined by Novartis Venture Fund, Breakthrough Victoria, Uniseed, UniSuper, and Agati Capital. Its future revenue model contemplates one-time product licensing and pharmaceutical sales of PVX108 and pipeline food-allergy immunotherapies following regulatory approval, distributed eventually through allergists, immunologists, specialty pharmacies, and healthcare providers. Commercial readiness is being built through a UK subsidiary at the Oxford Science Park (established November 2024) for peptide manufacturing process development, alongside senior commercial, regulatory, and CMC hires. Aravax's go-to-market motion today centers on international clinical trial execution (Phase 2 under US IND and Australian regulatory frameworks), scientific engagement at conferences such as EAACI and AAAAI, and academic collaborations with Stanford, Benaroya Research Institute, and Murdoch Children's Research Institute.

Aravax firmographics

Firmographics
Name
Aravax
Legal name
Aravax Pty Ltd
Website
https://aravax.com.au
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy designed to safely retrain the immune system to tolerate peanut allergens. The Melbourne-headquartered firm is running an international Phase 2 trial in children and adolescents ahead of a future commercial launch targeting allergists and food-allergy patients.
Ownership category
akta.pro rank

Aravax industry classification

Industry
Product category
Allergy Immunotherapy Pharmaceuticals
akta.pro industry
PRIMARYHLAKAAAF
Allergen Immunotherapy (SCIT/SLIT) Services

Keywords

  • Peptide immunotherapy
  • Peanut allergy treatment
  • Biopharmaceutical research
  • Food allergy therapies
  • Clinical stage biotechnology

Where Aravax is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Aravax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Revenue (Future): Pre-commercial biotech company. Future revenue expected from sale of PVX108 and pipeline immunotherapy products for food allergies upon regulatory approval. The company is preparing for Phase 3 trials and eventual market launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Aravax product offering

Product offering

Core offering

Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy composed of seven proprietary peptides targeting T cells for the treatment of peanut allergy. The therapy is delivered via monthly intradermal injection and is designed to retrain the immune system to tolerate peanut proteins without triggering treatment-induced acute allergic reactions. The company is currently running international Phase 2 clinical trials in the US and Australia and is preparing for Phase 3 development.

Product overview

Aravax is a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy. Its lead product candidate, PVX108, is a peptide-based immunotherapy in Phase 2 clinical trials for peanut allergy treatment. The company's proprietary platform uses engineered peptides to precisely target T cells and retrain the immune system to tolerate specific foods without triggering treatment-induced allergic reactions.

Differentiator

Problem solved

Functional benefit

Products and services

  • PVX108 PVX108 is Aravax's lead peanut allergy immunotherapy candidate, composed of seven proprietary peptides representing immuno-dominant T cell epitopes from major peanut allergens. It is designed to retrain the immune system to tolerate peanut proteins by precisely targeting allergen-specific T cells, while avoiding the acute allergic reactions triggered by whole-allergen therapies. It is administered monthly via intradermal injection (0.1 mL) with no dose escalation required, and is being developed for children and adolescents (aged 4-17) with peanut allergy.

Quantifiable outcome

  • Phase 1 trials demonstrated PVX108 was safe and well tolerated in participants with peanut allergy, including participants with asthma and prior anaphylaxis to peanut
  • +2 more outcomes

Companies that use Aravax

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Aravax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aravax partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • Benaroya Research InstitutecoreStrategic or Co-development PartnerResearch collaboration established January 2017. Erik Wambre's research group in Seattle collaborates on immunological response research. BRI received $5M NIH grant to support investigations into immune mechanisms of PVX108.
  • Stanford UniversitycoreStrategic or Co-development PartnerResearch collaboration established November 2017 with Professor Kari Nadeau's group at Sean N. Parker Centre for Allergy and Asthma Research. Collaborates on exploring immunological responses to PVX108 using clinical samples from trials.
  • Monash UniversitycoreTechnology or IntegrationTechnology and IP originated from Monash University and Alfred Health in 2015. Co-founder Sara Prickett held senior research posts here.
  • Alfred HealthcoreTechnology or IntegrationTechnology and IP originated from Alfred Health and Monash University in 2015. Research led by Professor Robyn O'Hehir's team.
  • Murdoch Children's Research InstitutesupportingStrategic or Co-development PartnerClinical trial site for Phase 2 (AVX-201) led by Associate Professor Kirsten Perrett. Also leads National Allergy Centre of Excellence.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Aravax competitors and assessment

Company assessment

Broad incumbents

  • Circassia Pharmaceuticals: Circassia is a UK-based allergy and respiratory specialty pharmaceutical company with a portfolio of allergy diagnostics and treatments. Several Aravax executives (Pascal Hickey, Paul Laidler, Adrian Parry, Louise Peacock) previously held senior roles at Circassia, indicating deep talent and strategic overlap in allergy therapeutics.
  • Stallergenes Greer: Stallergenes Greer is a global leader in allergen immunotherapy, offering SCIT and SLIT products for respiratory and venom allergies. It is a broader incumbent in the allergy immunotherapy category relevant to Aravax's target market of allergists and represents the established commercial infrastructure Aravax will eventually need to compete with or partner through.
  • ALK-Abello A/S: ALK-Abello is the dominant global player in allergy immunotherapy (SCIT/SLIT tablets) and the most established commercial competitor in the broader allergy space. Carsten Hellmann, former CEO of ALK-Abello, is on Aravax's board, signaling strategic overlap and a potential partnership/acquisition path.

Emerging players

  • Intrommune Therapeutics: Intrommune is developing a peanut allergy immunotherapy delivered via a toothpaste-based oral mucosal platform. It is an emerging player in the peanut allergy space using a differentiated delivery mechanism but targeting the same patient population.
  • Vedanta Biosciences: Vedanta is developing microbiome-based immunotherapies including for food allergy. While mechanism differs (commensal bacteria vs peptide), it targets the same underlying indication category and represents an emerging competitive approach in food allergy treatment that Aravax will need to position against.
  • Prota Therapeutics: Prota Therapeutics (formerly Prota Kids) is developing peanut oral immunotherapy with a probiotic-based approach, in clinical-stage development for peanut allergy. It is a direct emerging competitor in peanut allergy immunotherapy with overlapping indication and allergy-specialist channel.
  • COUR Pharmaceuticals: COUR Pharmaceuticals develops nanoparticle-based antigen-specific immune tolerance therapies for food allergies including peanut. It represents an emerging approach (antigen-loaded nanoparticles) intersecting with Aravax's peptide immunotherapy space in the same indication and prescriber audience.

Direct peers

  • Aimmune Therapeutics: Aimmune developed and commercialized Palforzia, the first FDA-approved oral immunotherapy for peanut allergy. It is the most directly comparable company to Aravax in peanut allergy immunotherapy, with overlapping target indication and clinical-stage development path. Andrew Oxtoby (now on Aravax's board) was previously CCO at Aimmune.
  • Alladapt Immunotherapeutics: Alladapt is developing a multi-food allergen immunotherapy for peanut plus other foods, with a similar mechanism approach (allergen-specific immune modulation). Louise Peacock, Aravax's Chief Regulatory and Quality Officer, previously held the same role at Alladapt, indicating direct competitive and talent overlap.
  • DBV Technologies: DBV develops Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. It is a direct competitor in the food allergy immunotherapy space using an alternative delivery modality (patch vs Aravax's intradermal peptide), targeting the same patient population and allergist channel.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Aravax social profiles

Digital presence

Aravax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aravax leadership team

Management profile

Number of profiles

Profiles17 records

Aravax subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aravax funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aravax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aravax

What does Aravax do?

Aravax is a clinical-stage biotechnology company developing PVX108, a peptide-based immunotherapy composed of seven proprietary peptides targeting T cells for the treatment of peanut allergy. The therapy is delivered via monthly intradermal injection and is designed to retrain the immune system to tolerate peanut proteins without triggering treatment-induced acute allergic reactions. The company is currently running international Phase 2 clinical trials in the US and Australia and is preparing for Phase 3 development.

Is Aravax a public or private company?

Aravax is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aravax founded?

Aravax was founded in 2015. It employs 11 to 50 people.

Where is Aravax based?

Aravax is headquartered in Melbourne, Australia, in the Oceania region.

How does Aravax make money?

One revenue line is on record: pharmaceutical Product Revenue (Future).

Who are Aravax's main competitors?

Broad incumbents on record are Circassia Pharmaceuticals, Stallergenes Greer and ALK-Abello A/S. Emerging players are Intrommune Therapeutics, Vedanta Biosciences, Prota Therapeutics and COUR Pharmaceuticals. Direct peers are Aimmune Therapeutics, Alladapt Immunotherapeutics and DBV Technologies.

Does Aravax have an API?

No public API is recorded for Aravax.

What industry is Aravax in?

Aravax's product category is Allergy Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAKAAAF, Allergen Immunotherapy (SCIT/SLIT) Services.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsAravax Reports Positive Phase 2 Results for Peanut Allergy Therapy PVX108Aravax reported positive Phase 2 results for PVX108, a peanut allergy immunotherapy, in children aged 4-11. The 50nmol dose significantly increased maximum tolerated peanut dose (2.4-fold vs 1.2-fold) and reduced reaction severity, with 39.4% tolerating ≥443mg protein versus 16.7% placebo. Results will be presented at ACAAI in November 2026.Business & FinancialAravax Announces Positive Results Of Phase 2 Clinical Trial Of PVX108, A Novel Immunotherapy For The Treatment Of Peanut AllergyAravax announced positive topline results from its Phase 2 trial of PVX108 for peanut allergy, with 96% of children completing treatment. The 50nmol dose increased the maximum tolerated peanut dose 2.4-fold versus placebo, and 39.4% tolerated ≥443mg protein versus 16.7% in placebo. Results will be presented at ACAAI in November 2026.PMLiVEFDA grants Fast Track status for peanut allergy immunotherapyThe US FDA has granted Fast Track designation to Aravax's PVX108, an investigational peptide-based immunotherapy for treating peanut allergy. The therapy is currently undergoing Phase 2 clinical trials in the United States and Australia, with key data expected later in 2026.Mirage NewsFDA Grants Fast Track to Aravax's PVX108 for Peanut AllergyAravax, a clinical-stage biotechnology company headquartered in Melbourne, Australia with operations in Oxford, UK, has received Fast Track designation from the US Food and Drug Administration for its lead product PVX108, a next-generation immunotherapy for peanut allergy. The Fast Track designation enables more frequent FDA interactions and eligibility for Accelerated Approval, Priority Review, and Rolling Review, potentially accelerating the drug's path to market. Phase 2 studies of PVX108 are ongoing at clinics in the United States and Australia, with key data anticipated later in 2026.GlobeNewswireAravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut AllergyAravax, a clinical-stage biotechnology company headquartered in Melbourne, Australia with operations in Oxford, UK, has received Fast Track designation from the US FDA for its lead product PVX108, a next-generation immunotherapy for peanut allergy. The FDA's Fast Track program facilitates expedited development and review of drugs for serious conditions and provides eligibility for Accelerated Approval, Priority Review, and Rolling Review. Phase 2 studies of PVX108 are ongoing at clinics in the United States and Australia, with key data anticipated later in 2026.GlobeNewswireAravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut AllergyAravax received FDA Fast Track designation for PVX108, a next-generation immunotherapy for peanut allergy. The designation enables more frequent FDA meetings and eligibility for accelerated approval. Phase 2 studies are ongoing in the US and Australia, with key data expected later in 2026.PR NewswireFood Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsightThe food allergy market is projected to grow from $2.7 billion in 2025 to $2.7 billion by 2036 at a 9.4% CAGR. Emerging therapies include DBV's Viaskin patch, Novartis' remibrutinib, and GSK's ozureprubart, with Phase III trials underway. Launches are expected to intensify competition and drive steady growth.GlobeNewswireAravax Strengthens Board with Appointments of Carsten Hellmann and Andrew OxtobyAravax appointed Carsten Hellmann and Andrew Oxtoby to its Board of Directors. Both bring extensive allergy-therapeutics experience, including Palforzia's launch and ALK-Abello's leadership. The appointments aim to support Aravax's Phase 3 development of PVX108 for peanut allergy.GlobeNewswireAravax Strengthens Board with Appointments of Carsten Hellmann and Andrew OxtobyAravax, a clinical-stage biotechnology company developing disease-modifying immunotherapies for food allergy, announced the appointment of Carsten Hellmann and Andrew Oxtoby to its Board of Directors. Carsten brings experience from nearly a decade as President & CEO of ALK-Abello A/S (world leader in allergy immunotherapy, ~3,000 employees, $6B+ market cap), while Andrew led the global commercial launch of Palforzia, the first approved peanut allergy treatment, at Aimmune Therapeutics. The appointments are intended to support Aravax through Phase 3 preparation, with Phase 2 results for lead product PVX108 forthcoming.BioSpaceAravax Strengthens Board with Appointments of Carsten Hellmann and Andrew OxtobyAravax, a clinical-stage biotechnology company developing food allergy immunotherapies, announced the appointment of Carsten Hellmann and Andrew Oxtoby to its Board of Directors. Hellmann is the former President & CEO of ALK-Abello A/S, a world leader in allergy diagnostics with a market cap of over US$6 billion, while Oxtoby is the former Chief Commercial Officer and later President & CEO of Aimmune Therapeutics, which was acquired by Nestle Health Science. Both appointees bring deep expertise in allergy therapeutics development and commercialisation to support Aravax's preparation for Phase 3 trials and beyond.